|Bid||13.51 x 900|
|Ask||13.52 x 800|
|Day's range||13.45 - 13.70|
|52-week range||8.78 - 14.27|
|Beta (5Y monthly)||1.31|
|PE ratio (TTM)||4.31|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||14.00|
Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.